First evaluation [n (%)] Day 46 | |||||
Response | Group A–0.6 mg | Group B- 1.2 mg | Group C-1.8 mg | Group D-2.4 mg | Total |
n = 3 | n = 6 | n = 5 | n = 6 | n = 20 | |
CR | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
PR | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
SD | 3(100%) | 4(67%) | 3(60%) | 5(83%) | 15(75%) |
PD | 0(0%) | 2(33%) | 2(40%) | 1(17%) | 5(25%) |
Second evaluation [n (%)] Day 106 | |||||
Response | Group A–0.6 mg | Group B- 1.2 mg | Group C-1.8 mg | Group D-2.4 mg | Total |
n = 3 | n = 5 | n = 3 | n = 4 | n = 15 | |
CR | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
PR | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) |
SD | 3(100%) | 3(60%) | 2(67%) | 4(100%) | 12(80%) |
PD | 0(0%) | 2(40%) | 1(33%) | 0(0%) | 3(20%) |